Multimodal techniques for diagnosis and prognosis of Alzheimer's disease.
Alzheimer's disease affects millions of people around the world. Currently, there are no treatments that prevent or slow the disease. Like other neurodegenerative diseases, Alzheimer's disease is characterized by protein misfolding in the brain. This process and the associated brain damage begin years before the substantial neurodegeneration that accompanies dementia. Studies using new neuroimaging techniques and fluid biomarkers suggest that Alzheimer's disease pathology can be detected preclinically. These advances should allow the design of new clinical trials and early mechanism-based therapeutic intervention.
Perrin
Richard J
RJ
Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St Louis, Missouri 63110, USA.
Fagan
Anne M
AM
Holtzman
David M
DM
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D018384:Oxidative Stress; D011379:Prognosis; D040901:Proteomics; D016875:tau Proteins / Q000134:cerebrospinal fluid / Q000378:metabolism
D016229:Amyloid beta-Peptides; D016875:tau Proteins